America's Blood Centers®
It's About Life.

ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2025 #21 **June 30, 2025**

INSIDE:

Blood Advocacy Week 2025 Recap 2
REGULATORY NEWS....3
WORD IN WASHINGTON 4
PEOPLE.....5
MEMBER NEWS.....5
Register for the July ABC Webinar: "Emerging Infectious Diseases & Malaria Risks: Updates for Blood Centers" 6
SAVE THE DATE: ABC WELC *Rise & Lead Workshop* November 13th-14th 6
SAVE THE DATE: 2025 ADRP Master Class September 24th-25th.....6
RESEARCH IN BRIEF 7
GLOBAL NEWS 7
COMPANY NEWS 8
CALENDAR.....9
POSITIONS.....10

Please Note: The *ABC Newsletter* will not be published on July 7th. We will resume regular publication on Monday, July14th. Thank you for your continued interest.

Authors in *Transfusion* Explore Factors Associated with Syphilis in U.S. Blood Donors

A paper published in *Transfusion* used the, "Transfusion-Transmissible Infections Monitoring System (TTIMS) datasets to investigate contemporary demographic and behavioral risk factors associated with active syphilis infections (ASI) in U.S. blood donors. A conceptual framework analysis was also developed to explore determinants in the causal pathways of ASI, including mediators and complex variables that may not be entirely captured by surveys or other traditional research instruments." The authors explained that, "[d]uring the study period there were 2,249 eligible ASI cases, from whom 130 females and 239 males were interviewed between July 2021 and October 2023." The study found that the, "age between 40 and 54 years old (compared to 55 and older), Black race (compared to White), lower income, being separated, divorced, or widowed, or being single (compared to married or living together), first-time (FT) donation, having ≥2 male or female sex partners, gay or homosexual orientation, and a history of STI were associated with increased odds of ASI. [Also, the authors noted that,] donors were probed about having sex while intentionally chemically impaired, a somewhat broader concept than the usual chemsex definition. These exposures have not been previously described in association with syphilis in U.S. blood donors. The potential inclusion of specific questions concerning the use of psychoactive substances to enhance sexual experiences should be explored for inclusion in the DHQ."

The paper concluded that the, "findings establish a baseline for future comparisons of exposures associated with ASI among U.S. blood donors, and potentially to compare with surveillance efforts from the general population from which blood donors are a subset. Our findings may also be used as a reference to refine the donor history questionnaire (DHQ), to implement education/prevention interventions targeting more vulnerable subgroups, and to improve communication between blood collection organizations and donors by informing not only the factors that may predict active syphilis infection, but also the relationship between distal and direct determinants of infection. Future analyses should explore the geographic influences on ASI as well as potential motivators for donation." The authors explained that limitations of their study included, "[w]e enrolled 16 percent of all eligible cases, and the comparison of enrolled, refused, and lost to follow-up showed significant sociodemographic differences beyond region of residency. The percentage of donors with coinfections was lower among enrolled cases, suggesting that donors with higher risk behaviors were not included; it is possible that some exposures,

(continued on page 2)

Authors in *Transfusion* Explore Factors Associated with Syphilis in U.S. Blood Donors (continued from page 1)

particularly those concerning sensitive information, were underreported. Because the outcome status was known, underreporting of exposures was potentially differential for cases and controls; our selection strategy may also have failed to select donors with very recent syphilis acquisition, with antibody responses still nonreactive; [and] [o]ur selection strategy may also have failed to select donors with very recent syphilis acquisition."

Citation: Avelino-Silva, V.I, Bruhn, R.L. Kaidarova, Z. *et al*. "Factors associated with active syphilis infection in U.S. blood donors." *Transfusion* 2025.

Blood Advocacy Week 2025 Recap

Earlier this month, America's Blood Centers (ABC) held Blood Advocacy Week 2025. Over the course of five days, ABC members, partners, sponsors, and other stakeholders united to advocate for policies that highlighted the importance of blood for patients, communities, and the healthcare system.

This year's event also featured the first ABC Advocacy Summit where participants learned from experts and peers how to advocate at the federal level, build stronger connections, while having the opportunity to meet with members of Congress and their staff to advance the blood community's advocacy efforts.

In addition to hearing insightful ways to advance their advocacy efforts with government partners, attendees received tips from leading experts in healthcare policy and government affairs, and former members of Congress on developing relationships with elected officials. Participants also engaged in panel discussions that covered best practices and strategies to advocate and articulate ABC member blood centers' priorities.

Highlights included:

- more than 100 organizations taking part in Blood Advocacy Week;
- advocates from 25 states joining us for our inaugural two-day Advocacy Summit;
- more than 125 bipartisan Congressional meetings were held;
- a successful blood drive on Capitol Hill inspired lawmakers, staff, and more to donate; and
- our media campaigns reached over 100 million readers nationwide.

ABC member Inova Blood Donor Services and Rep. Jim McGovern (D-Mass.) partnered with ABC to host the blood drive on Capitol Hill for members of Congress and congressional staff. The drive welcomed a total of 52 donors and resulted in the collection of 48 donations. This blood drive also provided an opportunity to remind staffers of the ongoing need for blood donations and allowed ABC to expand relationships with key Congressional offices.

(continued on page 3)

Blood Advocacy Week 2025 Recap (continued from page 2)

ABC thanks and congratulates all members, partners, sponsors, and participants for making Blood Advocacy Week 2025 our most successful and impactful yet! Your tremendous support through each meeting, donation, and conversation has brought us closer to our shared goal of ensuring a safe and available blood supply. We hope you help us carry this momentum forward as our advocacy work is ongoing. Your continued support is both needed and invaluable!

REGULATORY NEWS

On June 26th, the U.S. Food and Drug Administration (FDA) published a notice in the *Federal Register* announcing the release of a final guidance titled "Conducting Remote Regulatory Assessments-Questions and Answers; Guidance for Industry; Availability." According to the agency, the final guidance explains how, "FDA will use Remote Regulatory Assessments (RRAs) for FDA-regulated products. An RRA is an examination of an FDA-regulated establishment and/or its records, conducted entirely remotely, to evaluate compliance with applicable FDA requirements. Some of these tools include remote records requests." Changes from the previous draft guidance published in January 2024 aim to:

- distinguish more clearly between mandatory and voluntary RRA requests;
- clarify how FDA intends to inform establishments of the terms of participation in voluntary RRAs and obtain their consent;
- facilitate transparency and consistency in FDA's use of RRAs across regulated products, as applicable;
- clarify mechanisms for electronic records reviews and conditions under which live data access might occur; and
- address concerns about confidentiality and security of information reviewed by FDA."

The FDA further explained that the, "guidance lists several benefits of RRAs, including the potential for decreased inspection time and faster regulatory decisions involving product applications and compliance. The FDA uses a robust, risk-based oversight approach to ensure the continued safety of the nation's food and medical product supply. RRAs have enabled the agency to provide oversight to as many facilities as possible when travel was restricted while continuing to deploy our resources where possible to protect consumers and patients and promote public health…Due to the success of these tools, the agency will continue to use RRAs, as appropriate, in overseeing regulated industry and ensuring the safety and effectiveness of all types of regulated products, supplementing critical oversight tools such as inspections."

(Source: *Federal Register* Notice, 6/26/25)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail.

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers
Chief Executive Officer: Kate Fry
Chief Medical Officer: Jed Gorlin
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: $420

Send subscription queries to
memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.

WORD IN WASHINGTON

A paper published in *Health Affairs* titled, "National Health Expenditure Projections, 2024–33: Despite Insurance Coverage Declines, Health To Grow As Share Of GDP," explained that national health expenditures are, "projected to have grown 8.2 percent in 2024 and to increase 7.1 percent in 2025, reflecting continued strong growth in the use of health care services and goods." The authors of the paper reported on data from the Centers for Medicare and Medicaid Services (CMS). The paper also described that, "[n]ational health spending is expected to grow 5.4 percent in 2026 and 5.7 percent in 2027, which are slower rates of growth than the increase of 7.1 percent in 2025…In 2024, hospital spending growth is projected to have slowed but to have remained somewhat elevated, at 9.2 percent (compared with 10.4 percent in 2023), with expenditures of $1.7 trillion. For 2025, overall hospital spending growth is projected to slow further, to 6.8 percent [while in 2026-27,] average growth in overall hospital spending is projected to slow to 5.2 percent. [For 2028–33,] the remainder of the projection period, overall hospital spending growth is expected to average 5.5 percent annually." The authors concluded that, "[r]ecent elevated health care spending growth rates are expected to have continued into 2024 and 2025 because of persistently strong growth in the use of services and goods after their respective declines in 2020, which stemmed from the COVID-19 pandemic. As a result of these elevated rates of health care spending growth, relatively larger increases in the health share of GDP are projected for both 2024 and 2025. For 2026 and later, the growth rates for utilization and spending are generally expected to moderate…Although the projections presented here reflect current law, future legislative and regulatory health policy changes could have a significant impact on the projections of health insurance coverage, health spending trends, and related cost-sharing requirements, and they thus could ultimately affect the health share of GDP by 2033."

The U.S. Food and Drug Administration (FDA) has announced the publication of a white paper titled "Securing Technology and Equipment (Operational Technology) Used for Medical Product Manufacturing." According to the agency, the white paper aims to raise awareness that, "[m]anufacturing infrastructure increasingly includes numerous connected devices, considered Operational Technologies (OT), which have historically been designed to prioritize consistent functionality over cybersecurity. Consequently, it is sometimes difficult to tell what, when, and where network communications occur - potentially increasing the risk of a cybersecurity incident. Making state-of-the-art cybersecurity standards part of industry best practices for manufacturers of all sizes will help to considerably reduce the vulnerability of U.S. medical production and its supply chain."

(Source: FDA White Paper, 6/20/25)

Jacqueline Corrigan-Curay JD, MD, acting director of the FDA's Center for Drug Evaluation and Research (CDER) has announced that she is retiring from the agency in July, according to a report from *STAT News*. She became acting director in January 2025. Prior to that she had served as CDER's Principal Deputy Center Director since July 2021 and joined the FDA in October 2016 as CDER's Director for the Office of Medical Policy (OMP). "In that role, she led the development, coordination, and implementation of medical policy programs and strategic initiatives," according to her FDA bio.

(Source: *STAT News,* "Top drug regulator is retiring as FDA departures mount," 6/23/25)

PEOPLE

Miller-Keystone Blood Center has announced that **Kip Kuttner, DO** will retire as medical director at the end of the calendar year. Dr. Kuttner's career at the blood center spans 31 years. Miller-Keystone Blood Center President and Chief Executive Officer Rami Nemeh shared in the announcement that Dr. Kuttner will be, "leaving behind a legacy of excellence, compassion, and unwavering commitment. Throughout his remarkable career, Dr. Kuttner has been far more than a medical director, serving as a steadfast guardian of the health and safety of both our blood donors and staff. His unwavering dedication to upholding the highest standards of care has been instrumental in establishing Miller-Keystone Blood Center as a benchmark of excellence within the blood banking industry. Dr. Kuttner's expertise and visionary direction have helped to shape our present-day operations and laid a strong foundation for the continued growth and evolution of our organization." Mr. Nemeh added that, "beyond our immediate community, Dr. Kuttner has emerged as a respected and influential voice in shaping national blood banking practices. A tireless advocate for excellence in transfusion medicine, he has served many prestigious national committees, helping to craft policies and best practices that have guided the field forward. His contributions have not only elevated our organization's profile but have also helped to advance blood banking standards. Notably in recent years, he has chaired the America's Blood Centers (ABC) Scientific, Medical, and Technical (SMT) Committee, served with distinction as President of the New Jersey Association of Blood Bank Professionals (NJABBP), and contributed his expertise to the Association for the Advancement of Blood & Biotherapies (AABB) Committee for the *Circular of Information* for the Use of Human Blood and Blood Components. These roles reflect not only his deep knowledge and commitment to the field but also the high regard in which he is held by his peers across the nation...We look forward to honoring Dr. Kuttner's numerous contributions before his last day with us on December 31st and wish him all the best as he begins this next chapter."

(Source: Miller-Keystone Blood Center Announcement, 6/24/25)

MEMBER NEWS

Inova Blood Donor Services recently held their annual blood donor and coordination recognition dinner. ABC Chief Executive Officer Kate Fry, MBA, CAE was in attendance and honored Inova with an America's Blood Centers (ABC) Distinguished Recognition Award for their, "dedicated service to the community and the patients [served, commending Inova's] exemplary contributions to ABC, the blood community, and the advancement of evidence-based medicine."

(Source: ABC Announcement 6/13/25)

Northern California Community Blood Bank (NCCBB) recently unveiled a new bloodmobile that is smaller in size and designed to assist NCCBB in reaching more rural areas, according to KRCR ABC-7. Funding for the bloodmobile was made possible in part by a grant, "from the Burg Foundation, along with a year and a half of community fundraising, smaller grants and numerous donations." NCCBB Director of Donor Resources Kyle Windham explained to the news organization that, "[t]his is going to allow us to go out and reach more people. It will allow us to get into places that we might not be able to get into due to size restrictions."

(Source: KRCR ABC-7, "Northern California Blood Bank launches new mobile unit to reach rural areas, 6/24/25)

America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

Register for the July ABC Webinar: "Emerging Infectious Diseases & Malaria Risks: Updates for Blood Centers"

Registration is open for the Tuesday, July 29th America's Blood Centers (ABC) Webinar: "Emerging Infectious Diseases & Malaria Risks: Updates for Blood Centers." This event will take place at 3 p.m. EDT and featured speakers include ABC Chief Medical Officer Jed Gorlin, MBA, MD and OneBlood Chief Medical Officer Rita Reik, MD, FCAP. Additional information and a link to registration are available to ABC members here. Please contact us with any questions.

(Source: MCN 25-033, 6/24/25)

SAVE THE DATE: ABC WELC *Rise & Lead Workshop* November 13th-14th

Rise & Lead
A WOMEN'S LEADERSHIP WORKSHOP

ABC is excited to announce that the 2025 ABC Women's Executive Leadership Community (WELC) *Rise & Lead Workshop* will take place November 13th-14th in San Antonio, Texas at the Westin Riverwalk. Book now to secure the discounted rate. Registration will open in August. This workshop is designed for women in leadership positions, emerging leaders, and professionals seeking personal and professional growth. It also welcomes individuals who want to cultivate diverse perspectives. Attendees will engage in an intimate, engaging, and interactive environment focused on networking, mentorship, and meaningful discussions on leadership and growth. Please contact us with questions.

SAVE THE DATE: 2025 ADRP Master Class September 24th-25th

Mark your calendars and join ADRP for the 2025 ADRP Master Class taking place September 24th-25th. This year's theme is "Building Brighter Experiences: Empowering Customers, Engaging Employees." In today's competitive market, organizations that prioritize both employee and customer experience gain a significant edge. A motivated and engaged workforce leads to improved customer interactions, higher satisfaction, and long-term brand loyalty. The customer experience starts with the employee experience. This year's featured speaker is Janice Honeycutt Herring, a former Regional Director of Operations, United Blood Services, now Vitalant. With 30+ years of experience in organizational change and leadership development, Janice will bring unparalleled insights to the blood banking industry. She is the founder and chief executive officer of Firecracker Leadership. Stay tuned for more information! Please contact us with questions.

RESEARCH IN BRIEF

***In Vitro* Quality of Cold Stored Platelets Containing Aggregates.** The aim of a study in *Vox Sanguinis* "was to determine whether the characteristics of the donor, donation process, or the component quality parameters had any impact on the formation of aggregates during cold storage." The authors explained that, "[l]eukoreduced apheresis platelets were collected, and platelet additive solution was added (60 percent PAS-E/40 percent plasma)." They wrote that, "[t]he components were [placed in] refrigerated storage (2–6°C) [for 21 days.]" The paper described that "[a] single dose from each donation containing aggregates was tested (n=44)…The control group was from cold stored platelets (CSP) (n=45) which [had no] aggregates at any time during storage." Additionally, the researchers explained that, "[a] subset of aggregated components (n=15) was tested before and after being [exposed to a] 200-µm filter…Visible aggregates were identified in 80 CSP (10.9 percent) from 44 donations. [The paper noted that the] median time of storage at which aggregates were identified was 16 days (range 4–21 days)." The authors wrote that, "[d]onor factors including age, body mass index, hemoglobin and platelet count were not statistically different between the groups…However, donors of aggregated components made significantly more platelet donations in the previous two years than the donors of control components…The platelet concentration at day 21 was similar between the groups (Control: 931 ± 136 $x10^9$/L; Aggregated: 928 ± 158 x 10^9/L; p=0.9198)…The pH was lower in the aggregated components compared to controls." Also, the paper noted that, "the abundance of GPIIb and GPIbα was lower on the platelets in components containing aggregates…The aggregated components contained a higher proportion of CD62P-positive and annexin-V-positive platelets than non-aggregated controls…The aggregated components contained twofold more CD61+/annexin-V+ extracellular vesicles than present in non-aggregated controls. Degranulation was evident from lower side scatter properties in the aggregated components (5490 ± 509), compared to controls (6568 ± 643; p <0.0001), as well as higher concentrations of CD62P, PF4, RANTES, CD40L and TGF-β1." The authors further explained that, "[t]he aggregated platelets demonstrate[ed] that they were more primed to spontaneously aggregate than controls…[T]he strength of the clot formed (maximum amplitude [MA]) was significantly lower in the aggregated components…While the majority of aggregates were removed by filtration, some small aggregates were still observable by eye post filtration." The study concluded that, "aggregates developed in approximately 10 percent of apheresis platelets…In the majority of cases, aggregates were identified following prolonged storage in the cold (>14 days), and the platelets within these components were more activated than in non-aggregated controls."

Citation: Johnson, L., Roan, C., Lei, P., *et al*. "Characterization of the in vitro quality parameters of cold stored platelets containing aggregates." *Vox Sanguinis*. 2025.

Contributed by Richard Gammon, MD

GLOBAL NEWS

The World Health Organization (WHO) has announced the, "first-ever global guideline on the management of sickle cell disease (SCD) during pregnancy, addressing a critical and growing health challenge that can have life-threatening consequences for both women and babies." The agency noted in a news release that guideline, "includes over 20 recommendations spanning:

- folic acid and iron supplementation, including adjustments for malaria-endemic areas;
- management of sickle cell crises and pain relief;
- prevention of infections and blood clots;
- use of prophylactic blood transfusions; and
- additional monitoring of the woman and the baby's health throughout pregnancy."

(Source: WHO News Release, 6/19/25)

(continued on page 8)

GLOBAL NEWS (continued from page 7)

A report in the *BBC* stated that a ransomware attack from June 2024 on NHS, the national health service, in the United Kingdom, that led to the disruption of operations and blood transfusions contributed to the death of a patient. According to the news organization, "[t]he patient safety incident investigation identified a number of contributing factors that led to the patient's death. This included a long wait for a blood test result due to the cyber-attack impacting pathology services at the time."

(Source: BBC, "Ransomware attack contributed to patient's death," 6/25/25)

MedTech Europe, the European trade organization for medical technology companies, recently issued a statement urging European policymakers to, "exempt medical technologies from any trade tariffs or export restrictions. We also call for medical technologies to be included and priority[z]ed in a 'Zero for Zero' tariff agreement on industrial goods or as part of any negotiated settlement seeking to eliminate tariffs on both sides of the Atlantic. Action is needed now to protect patients and preserve access to critical healthcare solutions." The organization explained in the statement that, "[m]edical technologies depend on complex global supply chains and advanced material sciences. Some devices require up to a thousand components sourced from various regions, e.g., patient monitoring, dialysis systems, in vitro diagnostic analy[z]ers, magnetic resonance imaging machines and many more. Raw materials and semi-finished parts are often moved between international production sites for speciali[z]ed processing. Tariffs or restrictions would disrupt these intricate chains and create ripple effects throughout the healthcare system. Replacing components is not a simple option. In some cases, no alternative exists. Where substitutes are possible, the process of revalidation is lengthy and resource-intensive to ensure the same high standards and safety are met. Delays to access to medical technologies ultimately affect patients."

(Source: MedTech Europe Statement, 6/18/25) ♦

COMPANY NEWS

BioMarin Pharmaceutical Inc. has released new long-term safety and efficacy data from a phase III trial of its gene therapy, Roctavian® (valoctocogene roxaparvovec-rvox), to hemophilia. According to a company news release, "GENEr8-1 trial demonstrated that durable bleed control and sustained factor VIII (FVIII) expression were maintained five years after treatment with [the gene therapy.] FVIII activity remained consistent with previously reported results, and no new safety signals were observed. Across the entire trial, no participants developed FVIII inhibitors or experienced thromboembolic events, and there were no treatment-related malignancies across the five years of the study. [Additionally, after five years,] FVIII activity was nearly stable compared to year four, with mean FVIII activity in the mild hemophilia range (one-stage assay = 24.0 IU/dL; chromogenic assay = 13.7 IU/dL); 73.5 percent of participants had FVIII levels in the mild hemophilia to normal range. The mean ABR for treated bleeds for the rollover population was 0.6 bleeds/year after year five. During year five, 77.8 percent of the remaining participants (n=108) in the rollover population had zero treated bleeds. At the end of year five, 81.3 percent (n=109) of participants remained off prophylaxis. [Also,] clinically relevant changes in health-related quality of life measures were observed over five years."

(Source: BioMarin Pharmaceutical Inc. News Release, 6/24/25)

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to **Grifols Diagnostic** for its DG Gel 8 Neutral card for, "the detection of antibodies to red blood cell antigens of human blood samples and for its use as a control microtube." It is for *in vitro* diagnostic use with the DG Gel System. The agency also notified Grifols that it has granted 510(k) clearance for the company's Erytra, "a fully-automated high-throughput analyzer designed to automate *in vitro* immunohematological testing of human blood utilizing

(continued on page 9)

COMPANY NEWS (continued from page 8)

DG Gel 8 card technology, including Blood Grouping, Antigen Typing, Antibody Screening, Antibody Identification, Antibody Titration, Compatibility Tests, and Direct Antiglobulin Tests." Additionally, FDA granted 510(k) clearance to Grifols for the Erytra Eflexis, [a] fully-automated analyzer designed to automate *in vitro* immunohematological testing of human blood utilizing DG Gel 8 cards technology, including Blood Grouping, Antigen Typing, Antibody Screening, Antibody Identification, Antibody Titration, Compatibility Tests, and Direct Antiglobulin Tests."

(Source: FDA Announcements, 6/25/25; 6/17/25; 6/17/25)

CALENDAR

Note to subscribers: *Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

2025

July 29. **America's Blood Centers (ABC) Webinar: "Emerging Infectious Diseases & Malaria Risks: Updates for Blood Centers."** A link to registration and more information are available to ABC members here.

Sept. 10-12. **6th European Conference on Donor Health and Management (ECDHM). Wijk aan Zee, the Netherlands.** Registration is open. More information available here.

Sept. 24-25. **2025 ADRP Master Class: "Building Brighter Experiences: Empowering Customers, Engaging Employees (Virtual).** More information is coming soon.

Oct. 12-15. **American Association of Tissue Banks (AATB) Annual Meeting. Atlanta, Ga.** More information is coming soon.

Oct. 14-15. **International Protein Forum. Old Town Alexandria, Va.** Registration opens in July.

Oct. 25-28. **AABB Annual Meeting. San Diego, Calif.** More information is coming soon.

Oct. 26-29. **Blood 2025 and the ISBT 36th Regional Congress. Perth, Australia.** More information available here.

Nov. 12. **2025 ADRP International Showcase.** More information coming soon.

Nov. 13-14. **2025 ABC Women's Executive Leadership Community (WELC) *Rise & Lead Workshop*.** More information available here.

Nov. 17-20. **American Society for Clinical Pathology (ASCP) Annual Meeting. Atlanta, Ga.** Registration is open. More information available here.

2026

Mar. 9-12. **2026 ABC Annual Meeting. Tucson, Ariz.** More information coming soon.

May 12-14. **2026 ADRP Annual Conference. Minneapolis, Minn.** More information coming soon.

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: $139 per placement for *ABC Newsletter* subscribers and $279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Medical Director. OneBlood, a nationally recognized blood center collecting over one million donations annually, is seeking an experienced, board-certified Blood Center **Medical Director**. This physician leader will join our team of Transfusion Medicine experts and play a pivotal role in advancing donor and patient safety, transfusion services, therapeutic apheresis, and research collaborations. Our position, located in the state of Florida, includes a competitive salary & benefits package, performance incentives, retirement plan with company contribution plus a company match, vehicle stipend, company-paid holidays, much more. Qualifications include a MD or DO degree, valid/current Florida Medical Doctor license, a minimum of one year of transfusion medicine experience, as well as board subspecialty certification in Blood Banking/Transfusion Medicine recognized by the American Board of Pathology (ABP) or equivalent, required. For a complete listing of required qualifications and job description and to apply, visit our ***Careers*** page at www.oneblood.org and search Medical Director to learn more.

Reference Laboratory Technologist. Be part of something bigger; change the world with us by joining **ImpactLife's** team. We are seeking a full-time **Medical Laboratory Scientist/Medical Technologist** to join our Blood Banking team. As a Reference Lab Tech with ImpactLife, you will work in our accredited immunohematology reference laboratory, performing specialized testing to serve local hospital clients. For more information including job details, benefits, and compensation click here: Join Us!

Vice President, Blood Services (Eastern and Western Area - Remote). Vitalant is looking for a bold, visionary leader to join our Blood Services Leadership Team as the **Vice President, Eastern Area**. This is a high-impact role, that will focus on deep community and customer engagement, mobile blood drive success, resource management for both mobile and fixed sites, with local facility and fleet oversight. This position works in a highly collaborative manner with leadership throughout the organization to ensure strategic and collection goals are met. **We're Looking for a Proven Senior Leader Who Can:** Translate enterprise strategy into local execution. Build and lead high-performing teams of senior and mid-level leaders. Cultivate a culture of accountability, learning, and cross-functional partnership. Balance operational excellence with innovation and adaptability. Inspire trust, transparency, and connection across regions and stakeholder groups. **What You Can Expect:** In this high-impact leadership role, you'll receive a **competitive compensation and total rewards package including a robust performance-based bonus plan**—reflecting your years of experience and the vital influence this position has on our mission and long-term success. If you're ready to make a measurable impact on public health through quality leadership, we invite you to join us. Interested applicants www.vitalant.org/careers.

Medical Laboratory Scientist. LifeSouth Community Blood Centers is looking for experienced Medical Laboratory Scientists, with a passion for making a difference. Current openings are in Gainesville, Florida (Overnight) and Atlanta, Georgia (Multiple shifts available; rotating weekends required). **Legal authorization to work in the United States is required. We do not provide visa sponsorship for this position.** Shift differential applies to eligible evening and overnight hours; **sign-on and relocation bonuses** may also be offered to qualified candidates. Our Medical Laboratory Scientists work in a full-service, accredited immunohematology laboratory following established policies and procedures to resolve complex immunohematology and compatibility problems to provide the safest donor blood for patients in our community. Join us in our mission to make sure blood is available when it's needed most. Visit our careers page to learn more about this position and apply today!

Laboratory Supervisor (Evenings). LifeSouth Community Blood Centers is looking for an experienced **Laboratory Supervisor** with a passion for making a difference to lead our evening shift Immunohematology Reference Laboratory team, in Gainesville, FL. Shift differential applies to eligible evening and overnight hours; **sign-on and relocation bonuses** may also be offered to qualified candidates. **Legal authorization to work in the United States is required. We do not provide visa sponsorship for this position.** In this role, you'll oversee daily operations, ensure adherence to established policies and procedures, and support staff in resolving complex testing and compatibility challenges. You'll play a critical part in identifying and addressing issues that may impact test performance or result reporting, while mentoring and guiding team members to uphold the highest standards of quality and safety. Your leadership will help ensure the delivery of the safest donor blood for patients in our community. We are committed to excellence in customer service and patient care. Join us in our mission to make sure blood is available when it's needed most. Visit our careers page to learn more about this position and apply today!

Quality Assurance Manager. Kentucky Blood Center (KBC) is seeking a Quality Assurance Manager to guide and support organizational adherence to standards issued by regulatory agencies and accrediting organizations. The position is responsible for KBC's compliance with applicable AABB, FDA, CLIA, State, OSHA, EU, and short supply agreement requirements. Reports to the Vice President, Quality and Regulatory Affairs; supervises the QA team. Qualifications include a minimum of a 4-year medical technologist degree (MLS/CLS) with ASCP professional certification and appropriate combination of experience. Must be located in, or willing to relocate to the Lexington, Kentucky area (assistance provided). For more information or to apply, visit https://www.kybloodcenter.org/about-us/careers.